The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1428849
This article is part of the Research Topic Molecular Studies and Therapeutic Approaches on BRCA-associated Cancers View all articles
BRCA2 Mutations in Familial Breast Cancer With Prostate Cancer: a Case Report and Literature Review
Provisionally accepted- 1 Bladder Cancer Research Centre (BCRC), Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- 2 Fujian Medical University, Fuzhou, Fujian Province, China
- 3 Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, China
- 4 Xiamen University, Xiamen, Fujian Province, China
Prostate cancer (PCa) is the second most common tumour in men globally. Its etiology has been attributed to multiple factors, including age and ethnicity, with family history identified as a significant risk factor. The role of family history in prostate cancer risk appears to be more extensive than previously thought, with evidence suggesting that prostate cancer and breast cancer may occur concurrently within families. BRCA2 mutations have been linked to an increased risk of prostate cancer, particularly in patients diagnosed with early-onset disease. It is estimated that BRCA2 mutations account for approximately 5% of familial prostate cancer cases. It is noteworthy that cases of prostate cancer in patients with BRCA2 mutations are rare in clinical practice. Here we report a case of prostatitis carcinoma with a mutation in the BRCA2 gene in a patient who underwent robotic-assisted radical prostatectomy for prostatitis carcinoma after medication was not effective. Genetic testing of him, his son, and his daughter showed that they all had mutations in this gene, and it is noteworthy that the type of BRCA2 mutation in his son has never been reported before, which is rare in clinical practice.
Keywords: BRCA2 mutations, BRCA2, Familial breast cancer, Familial prostate cancer, prostate cancer
Received: 07 May 2024; Accepted: 23 Aug 2024.
Copyright: © 2024 Liu, 黄, Ding, Wang, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tao Wang, Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian Province, China
Yuedong Chen, Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian Province, China
Kaiyan Zhang, Fujian Medical University, Fuzhou, 350108, Fujian Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.